Arvinas and Pfizer are the first to take a PROteolysis TArgeting Chimera (PROTAC) therapy across the FDA finish line, opening ...
Unionized workers at fast-growing South Korean CDMO Samsung Biologics kicked off a planned general strike on Friday, ...
Shortly after laying out $75 million upfront for Corstasis Therapeutics and its congestive heart failure edema drug Enbumyst, ...
Looking to clarify its expectations on manufacturer responses following inspections, the FDA earlier this year unveiled, for ...
Four years after gaining FDA approval for Auvelity to treat major depressive disorder (MDD), Axsome Therapeutics has tacked ...
Amgen CEO Robert Bradway has declared 2026 a “springboard year” for the California big biotech, in which the growth of its ...
A surprise interim trial miss in ivonescimab’s closely watched Harmoni-3 trial has sent Summit Therapeutics’ shares tumbling, ...
Sun Pharma will acquire Organon for $11.75 billion. Astellas projects Xtandi sales to decline in fiscal year 2026. | Sun ...
Novartis CEO Vas Narasimhan is doubling down on his $5 billion peak sales projection for Pluvicto, even as the company has ...
As Eli Lilly gets off to the races with the launch of its flagship oral GLP-1 Foundayo, the Indianapolis drugmaker—and at ...
As pharma giants slash headcounts and routinely strike billion-dollar M&A deals, another trend is steadily playing out at many of the largest drugmakers: the adoption of AI on a corporate scale. Count ...
The FDA has reprimanded Bayer for the “attention-grabbing visuals” and “frequent scene changes” in ads for the company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results